Immediate Impact

2 by Nobel laureates 1 from Science/Nature 51 standout
Sub-graph 1 of 25

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
2024 Standout
3 intermediate papers

Works of Won-Seog Kim being referenced

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
2022
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
2018

Author Peers

Author Last Decade Papers Cites
Won-Seog Kim 616 469 277 37 763
Reyes Arranz 508 368 232 36 743
Stephen T.H. Lo 506 391 247 24 869
Klaus Willenbrock 549 457 287 23 862
C Gisselbrecht 534 444 173 36 841
Kensaku Sato 483 415 188 27 735
Santiago Mercadal 545 390 153 55 681
Tiffany Tang 495 393 208 26 673
Glenn H. Segal 426 266 133 33 732
Woo‐Ick Yang 492 467 158 34 841
Manuela Zanni 623 371 142 35 694

All Works

Loading papers...

Rankless by CCL
2026